Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 3/20 | 0.81 |
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1640295 | 0.90 | EGLN3 (1.00) | EGLN3EGLN1MEN1KMT2ANPC1 | |
| SCHEMBL1642303 | 0.89 | EGLN3 (0.69) | EGLN3EGLN1MEN1KMT2ANPC1 | |
| SCHEMBL1642598 | 0.87 | EGLN3 (0.90) | EGLN3EGLN1MEN1KMT2AALDH1A1 | |
| SCHEMBL1641775 | 0.86 | EGLN3 (0.81) | EGLN3EGLN1MEN1KMT2AALDH1A1 | |
| SCHEMBL1660831 | 0.86 | EGLN3 (0.63) | EGLN3EGLN1MEN1KMT2ANPC1 | |
| SCHEMBL1640593 | 0.85 | EGLN3 (0.83) | EGLN3EGLN1 | |
| SCHEMBL1641948 | 0.84 | EGLN3 (0.60) | EGLN3EGLN1MEN1KMT2ANPC1 | |
| SCHEMBL1642011 | 0.84 | EGLN3 (0.88) | EGLN3EGLN1MEN1KMT2AALDH1A1 | |
| SCHEMBL1640549 | 0.82 | EGLN3 (0.78) | EGLN3EGLN1MEN1KMT2AL3MBTL1 | |
| SCHEMBL1642474 | 0.82 | EGLN3 (0.78) | EGLN3EGLN1KMT2APDE10AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN2, EGLN3 | EGLN3 3/4885EGLN1 6/4885MEN1 3669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.